The Association of the British Pharmaceutical Industry (ABPI) have responded to the Competition and Markets Authority (CMA) infringement decision on Pfizer and Flynn Pharma.
The CMA have imposed a record fine on Pfizer and a fine on distributor Flynn Pharma after coming to a decision that each broke competition law by charging "excessive and unfair prices" in the UK for an anti-epilepsy drug.
Pfizer has "refuted" the CMA findings and have said they "will be appealing all aspects of the Decision". Flynn Pharma will also be launching an appeal.
In response to the CMA decision, the ABPI have issued the following statement:
“The ABPI has repeatedly said that it does not in any way support or condone the practice of ‘price hikes’ to generic medicines. This position has not changed.
Whilst we can’t comment on individual companies and an appeal being made, it’s appropriate that the complexities of this case are considered through the ongoing legal process.”
ABPI Press OfficeEmail: email@example.comTelephone during work hours (9am to 5pm Monday to Friday): +44 (0) 20 7747 7147 or +44 (0) 20 7747 1441Telephone out of hours (5pm to 9am and weekends): +44 (0) 20 7747 1445
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.